key: cord-0728995-tk1l86wk authors: Manning, Thomas J.; Thomas-Richardson, Jenu; Cowan, Matthew; Beard, Torien title: Vaporization, bioactive formulations and a marine natural product: different perspectives on antivirals date: 2020-04-20 journal: Drug Discov Today DOI: 10.1016/j.drudis.2020.04.010 sha: 67adf4af1ee4f90e5322148c5bfa73b566790c7f doc_id: 728995 cord_uid: tk1l86wk This article examines three aspects of antivirals as they might relate to the treatment of COVID-19: (i) the use of vaporization for the delivery of antivirals, with the bulk constituents having mild antiviral efficacy; (ii) the application of a marine natural product extract as opposed to a single molecule as an antiviral agent; and (iii) a counter intuitive approach to formulation that is, in part, based on delivering multiple species that fall into three categories: building blocks for the virus to accelerate replication; an energy source for the infected cell to boast its immune response; and the species that antagonize or provide toxicity to the virus. Bioactive vapors composed oforganic species have the potential to deliver pharmaceutical agents efficiently and economically [1, 2] . This article focuses on the vaporization and delivery of hydroxychloroquine and bryostatin (two compounds with antiviral activity), their bioactive formulations and some details about the applications of a marine natural product as an antiviral agent. The administration of the drug is matched with hostspecific bioactive formulations. We discuss why the marine natural product bryostatin should be tested as a collection of molecular species found in nature and not a single active structure. Vaping for the delivery of nicotine and species found in 'vape juice' is a tremendous health risk; however, a similar device could be tested for antiviral drug delivery, incorporating the same bulk solutions for the treatment of viral infections. Hydroxychlor Q4 oquine and chloroquine, both antimalarial agents, are being investigated as potential treatments of COVID-19 [3] . The coronavirus results in severe acute respiratory syndrome (SARS) [4] , indicating an inhalation route using an aerosol or vapor might offer a more effective treatment method compared with a pill, i.v. or an implant, assuming the drugs can be delivered at acceptable doses with little or no side effects. A formulation that consists of three bulk constituents: 50% propylene glycol, 25% glycerin and 25% ethanol by volume, was tested as a method to deliver a unique set of formulations with anti-and pro-viral activities. Glycerin has been used to fix viruses for decades, propylene glycol has been shown to inactivate viruses and ethanol is widely used as a viral disinfectant. Ethanol is also added to increase the solubility of some of the polar species. Ammonium chloride, which can have a negative impact on the viral replication rate, is included at low levels [5] . Fatty acids including stearic, oleic, linoleic and arachidonic acids are included at <1% of the total mass. The state (s, l) and solubi Q5 lity of each species must be considered. It has been demonstrated that specific fatty acids can impact the replication rate of the coronavirus [6] . Human serum albumin provides a source of amino acids for the virus. When suspended in the solution, ethanol denatures the structure allowing it to decompose into its basic building blocks with less effort. ssDNA is added for its building blocks, which can be utilized by the virus. The two macromolecules comprise no more than 1% of the total mass. Fructose or glucose are included as an energy source for the infected cells, increasing their metabolic processes along with the uptake rate of the drug that attacks the viral population in an infected cell at a mass <1%. Hydroxychloroquine was tested at levels at high as 6% of the bulk solvent mass. In a typical formulation, the hydroxychloroquine or bryostatin extract was 4% of the bulk solvent mass and the other species a maximum of 3% of the solvent mass. In our experiments the bulk solvent contains different mixtures of the proposed antiviral and the bioactive ingredients are vaporized by a commercially available vape device (